Glad you posted, joey. There are lots of companies like AVXL that may (or may not) have some kind of great drug in their pipeline, but for whatever reason -- bad management, poor choices in how to run clinical trials, being targeted by short-seller cabals -- their drug never gets developed as it should have been. AVXL certainly seemed to be going down the path to disaster, but this new president may be setting them on the right course, or just delaying the disaster that is to come. No way of knowing now. I hope that AVXL is the "CTIX" in the story below, not the PolyMedix:

PolyMedix had this large pipeline of potential drugs. They had a novel class of antibiotics but stupidly tried it at massive doses instead of being cautious with initial dosages, so there were bad side effects. They decided to bet everything on some other drug instead of tweaking the antibiotic, the other drug failed, and ka-blooey ! ! company into bankruptcy. CTIX bought the intellectual property for a measly 5 million bucks, and after trying the antibiotic at much lower doses with no significant side effects, now they are developing 3 drugs for different applications from that one antibiotic alone -- and they have all the other intellectual property too.

So, PYMX did everything wrong both from business and scientific standpoints, and went kaput. It's going to be very painful for those shareholders if CTIX succeeds with the drug, as looks very likely.